2026-04-13T15:15:28Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/91082025-10-24T10:19:30Zcom_2072_378070com_2072_378040col_2072_378092

Cardiorenal benefits of finerenone: protecting kidney and heart Soler Romeo, Maria Jose Facila, Lorenzo Gorriz, Jose Luis Ortiz Arduan, Alberto González Juanatey, José Ramón Valle, Alfonso Institut Català de la Salut [González-Juanatey JR] Cardiology Department, Hospital Clínico Universitario Santiago de Compostela, Centro de investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Santiago de Compostela, Spain. [Górriz JL] Nephrology Department, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain. [Ortiz A] Nephrology Department, Fundación Jiménez Díaz, Madrid, Spain. [Valle A] Cardiology Department, Hospital La Salud, Valencia, Spain. [Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Facila L] Cardiology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain Vall d'Hebron Barcelona Hospital Campus Diabetis no-insulinodependent - Complicacions Insuficiència renal crònica - Complicacions Sistema cardiovascular - Malalties - Diagnòstic Antihormones DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2 DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency, Chronic DISEASES::Cardiovascular Diseases CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Mineralocorticoid Receptor Antagonists Other subheadings::Other subheadings::/therapeutic use ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::insuficiencia renal crónica ENFERMEDADES::enfermedades cardiovasculares COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de receptores de mineralocorticoides Otros calificadores::Otros calificadores::/uso terapéutico Albuminuria; Enfermedad renal crónica; Finerenona Albuminúria; Malaltia renal crònica; Finerenona Albuminuria; Chronic kidney disease; Finerenone Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis. Finerenone is a nonsteroidal selective mineralocorticoid antagonist. Recent clinical trials, such as FIDELIO-DKD and FIGARO-DKD and the combined analysis FIDELITY have demonstrated that finerenone decreases albuminuria, risk of CKD progression, and CV risk in subjects with type 2 diabetes (T2D) and CKD. As a result, finerenone should thus be considered as part of a holistic approach to kidney and CV risk in persons with T2D and CKD. In this narrative review, the impact of finerenone treatment on the CV system in persons with type 2 diabetes and CKD is analyzed from a practical point of view. 2023-03-03T13:33:11Z 2023-03-03T13:33:11Z 2023-01-31 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med. 2023 Jan 31;55(1):502–13. 1365-2060 https://hdl.handle.net/11351/9108 10.1080/07853890.2023.2171110 36719097 000919979500001 http://hdl.handle.net/11351/9108 eng Annals of Medicine;55(1) https://doi.org/10.1080/07853890.2023.2171110 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf Taylor & Francis Scientia